Trials / Terminated
TerminatedNCT00057343
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
A Prospectively Randomized, Phase III, Multicenter, Controlled Trial to Evaluate the Safety and Efficacy of the Zevalin Therapeutic Regimen Plus Rituxan Compared With Rituxan Alone in Patients With Relapsed or Refractory Follicular NHL
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (planned)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zevalin (ibritumomab tiuxetan) | |
| DRUG | Rituxan (rituximab) |
Timeline
- Start date
- 2003-03-01
- First posted
- 2003-04-01
- Last updated
- 2006-09-12
Locations
67 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00057343. Inclusion in this directory is not an endorsement.